TW200418803A - Anilinopyrazole derivatives useful for the treatment of diabetes - Google Patents

Anilinopyrazole derivatives useful for the treatment of diabetes Download PDF

Info

Publication number
TW200418803A
TW200418803A TW092133242A TW92133242A TW200418803A TW 200418803 A TW200418803 A TW 200418803A TW 092133242 A TW092133242 A TW 092133242A TW 92133242 A TW92133242 A TW 92133242A TW 200418803 A TW200418803 A TW 200418803A
Authority
TW
Taiwan
Prior art keywords
group
crc6
alkyl
alkoxy
optionally substituted
Prior art date
Application number
TW092133242A
Other languages
English (en)
Chinese (zh)
Inventor
Joachim Rudolph
Louis-David Cantin
Steven Magnuson
William Bullock
Ann-Marie Bullion
Libing Chen
Chih-Yuan Chuang
Sidney Liang
Dyuti Majumdar
Herbert Ogutu
Alan Olague
Ning Qi
Philip L Wickens
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of TW200418803A publication Critical patent/TW200418803A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW092133242A 2002-11-27 2003-11-26 Anilinopyrazole derivatives useful for the treatment of diabetes TW200418803A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
TW200418803A true TW200418803A (en) 2004-10-01

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092133242A TW200418803A (en) 2002-11-27 2003-11-26 Anilinopyrazole derivatives useful for the treatment of diabetes

Country Status (16)

Country Link
US (2) US7265144B2 (cg-RX-API-DMAC7.html)
EP (1) EP1567517A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006510728A (cg-RX-API-DMAC7.html)
KR (1) KR20050085170A (cg-RX-API-DMAC7.html)
AR (1) AR042067A1 (cg-RX-API-DMAC7.html)
AU (2) AU2003295890A1 (cg-RX-API-DMAC7.html)
BR (1) BR0316723A (cg-RX-API-DMAC7.html)
CA (1) CA2507186A1 (cg-RX-API-DMAC7.html)
HN (1) HN2003000379A (cg-RX-API-DMAC7.html)
MX (1) MXPA05004621A (cg-RX-API-DMAC7.html)
MY (1) MY141528A (cg-RX-API-DMAC7.html)
PE (1) PE20040907A1 (cg-RX-API-DMAC7.html)
PL (1) PL377164A1 (cg-RX-API-DMAC7.html)
TW (1) TW200418803A (cg-RX-API-DMAC7.html)
UY (1) UY28098A1 (cg-RX-API-DMAC7.html)
WO (2) WO2004050650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567352A1 (en) * 2004-05-20 2005-12-01 Bayer Pharmaceuticals Corporation 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
EP1860098B1 (en) 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
CA2620425A1 (en) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
ATE550326T1 (de) * 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
CA2698928A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
WO2010033360A1 (en) * 2008-09-19 2010-03-25 1/3 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
MX2011002793A (es) 2008-09-25 2011-04-05 Hoffmann La Roche Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indaz ol.
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
EP3805213A3 (en) 2015-06-18 2021-06-09 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
KR102420892B1 (ko) * 2017-05-26 2022-07-14 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 요산 배출을 촉진시키는 urat1 억제제
WO2020227368A1 (en) * 2019-05-08 2020-11-12 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134200C (cg-RX-API-DMAC7.html) 1960-04-14
US3790576A (en) 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
HUT69739A (en) 1992-03-26 1995-09-28 Dowelanco Process for producing n-heterocyclic nitroanilines and fungicides containing the compounds
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
EP1597234B1 (en) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
US7265144B2 (en) 2007-09-04
CA2507186A1 (en) 2004-06-17
HN2003000379A (es) 2005-12-20
AU2003297565A1 (en) 2004-06-23
UY28098A1 (es) 2004-06-30
AU2003295890A1 (en) 2004-06-23
US20040157904A1 (en) 2004-08-12
US20080064734A1 (en) 2008-03-13
KR20050085170A (ko) 2005-08-29
WO2004050651A1 (en) 2004-06-17
PE20040907A1 (es) 2005-01-27
EP1567517A1 (en) 2005-08-31
MY141528A (en) 2010-05-14
PL377164A1 (pl) 2006-01-23
WO2004050650A1 (en) 2004-06-17
BR0316723A (pt) 2005-10-18
AR042067A1 (es) 2005-06-08
JP2006510728A (ja) 2006-03-30
MXPA05004621A (es) 2005-06-08
HK1087103A1 (zh) 2006-10-06

Similar Documents

Publication Publication Date Title
AU2020343671C1 (en) RIP1 inhibitory compounds and methods for making and using the same
CN117362283B (zh) Glp-1受体激动剂及其组合物和用途
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
TW202115076A (zh) 嘧啶并五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN103874492B (zh) 不对称脲及其医学应用
WO2007037534A1 (ja) 2-へテロアリール置換インドール誘導体
TW201028386A (en) Novel bicyclic heterocyclic compound
ES2982890T3 (es) Antagonistas del receptor muscarínico de acetilcolina M4
US20080064734A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW201113272A (en) Novel pyrimidine-and triazine hepcidine antagonists
TW200918521A (en) Heterocyclic amides and methods of use thereof
EA030085B1 (ru) 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
TW200836736A (en) Compounds and compositions as modulators of GPR119 activity
CN106905322A (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
TW200533664A (en) Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
RU2712163C2 (ru) Активатор kcnq2-5 каналов
TW201002708A (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP7098167B2 (ja) ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子
US11236055B2 (en) Non-systemic TGR5 agonists
TW202419090A (zh) Nlrp3炎症小體抑制劑及其應用
TWI710554B (zh) 新穎苯并咪唑化合物及其醫藥用途
TW200538130A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TWI300066B (en) Pharmaceutically active compounds
CN105683153B (zh) 用于治疗高血压和/或纤维化的组合物
WO2021043260A1 (zh) 嘧啶类化合物及其制备方法